It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and M&A news flow.
Now, here are the upcoming week’s key biotech catalysts.
Conferences
- 20th World Congress on Gastroenterology – March 4-5, in Berlin, Germany
- 18th International Conference on Nephrology & Urology – March 4-5, in Berlin
- 24th Annual meet on Surgical Oncology – March 4-5, in Paris, France
- 10th Molecular Immunology & Immunogenetics Congress – March 4-5, in Barcelona, Spain
- Credit Suisse 2019 Global Healthcare Conference – March 5-6, in London
- 32nd Euro Congress on Cancer Science & Therapy – March 7-8, in Barcelona
- 5th International Conference on Mental Health and Human Resilience – March 7-8, 2019 Barcelona
PDUFA Dates
The FDA is likely to rule on Johnson & Johnson JNJ 1.27% unit Janssen’s treatment-resistant drug Esketamine Monday. A FDA panel that reviewed the investigational drug voted 14-2 in favor of its benefit-risk profile.
Clinical Trial Results
Sesen Bio Inc SESN 9.47% is due to release additional preliminary Phase 3 data for Vicinium, its treatment candidate for non-muscle invasive bladder cancer Monday.
Myokardia Inc MYOK 6.44% will release additional interim Phase 2 data for its non-obstructive hypertrophic cardiomyopathy candidate Mavacamten Monday.
Earnings
Monday, March 4
- BioCryst Pharmaceuticals, Inc. BCRX 4.18% (before the market open)
- Sesen Bio (before the market open)
- Myokardia (before the market open)
- Adamas Pharmaceuticals Inc ADMS 5.45% (after the market close)
- La Jolla Pharmaceutical Company LJPC 1.93% (after the market close)
- Otonomy Inc OTIC 4.37% (after the market close)
Tuesday, March 5
- Aerpio Pharmaceuticals Inc ARPO 2.34% (before the market open)
- Chimerix Inc CMRX 13.3% (before the market open)
- Obseva SA OBSV 1.84% (before the market open)
- Neuronetics Inc STIM 0.86% (before the market open)
- Fate Therapeutics Inc FATE 5.54% (after the market close)
- BIOLASE Inc BIOL 0.39% (after the market close)
- Kura Oncology Inc KURA 0.46% (after the market close)
Wednesday, March 6
- GlycoMimetics IncNASDAQ: (GLYC) (before the market open)
- Jounce Therapeutics Inc JNCE 4.27% (before the market open)
- OptiNose Inc OPTN 7.28% (before the market open)
- Xenon Pharmaceuticals Inc XENE 3.49% (after the market close)
- Assertio Therapeutics Inc ASRT 4.59% (after the market close)
- CareDx Inc CDNA 1.61% (after the market close)
- Evoke Pharma Inc EVOK 0.97% (after the market close)
Thursday, March 7
- Orthopediatrics Corp KIDS 3.21% (before the market open)
- Albireo Pharma Inc ALBO 10.03% (before the market open)
- ArQule, Inc. ARQL 8.56% (before the market open)
- Zai Lab Ltd ZLAB 3.37% (before the market open)
- Syros Pharmaceuticals Inc SYRS 3.39% (before the market open)
- Celldex Therapeutics, Inc. CLDX 0.38% (after the market close)
- Kindred Biosciences Inc N(ASDAQ: KIN) (after the market close)
- Pure Bioscience, Inc. Common Stock PURE 7.4% (after the market close)
- Ocular Therapeutix Inc OCUL 4.94% (after the market close)
- Aeglea Bio Therapeutics Inc AGLE 2.75% (after the market close)
- AcelRx Pharmaceuticals Inc ACRX 9.23% (after the market close)
- Aravive Inc (NASDAQ: ARAV (after the market close)
- Arbutus Biopharma Corp ABUS 4.1% (after the market close)
- Geron Corporation GERN 4.79% (after the market close)
- HTG Molecular Diagnostics Inc HTGM 0.73%
- Syndax Pharmaceuticals Inc SNDX 2.92%
Friday, March 8
- Allogene Therapeutics Inc ALLO 1.42% (before the market open)
- Eloxx Pharmaceuticals Inc ELOX 5.06% (before the market open)
- PLx Pharma Inc PLXP 2.06% (before the market open)
IPO
ShockWave Medical, which sells medical devices to treat cardiovascular diseases, is set to offer 5 million shares in an IPO, with an estimated price range of $14-$16. The company expects to list its shares on the Nasdaq under the ticker symbol SWAV.
IPO Quiet Period Expiry
Alector Inc ALEC 7.15%
Harpoon Therapeutics IncHARP 6.53%
Gossamer Bio Inc GOSS 5.36%
ANCHIANO THERAP/S ADR ANCN
Harpoon Therapeutics IncHARP 6.53%
Gossamer Bio Inc GOSS 5.36%
ANCHIANO THERAP/S ADR ANCN
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.